Last reviewed · How we verify

NCT06365775

Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss

Not yet recruiting Last updated 15 April 2024
What this trial tests

trial in Sudden Sensorineural Hearing Loss in 400 participants. Not yet recruiting.

Timeline
23 April 2024
Primary endpoint
23 November 2026
23 November 2026

Quick facts

Lead sponsorDan Bing
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment400
Start date23 April 2024
Primary completion23 November 2026
Estimated completion23 November 2026

Conditions studied

Sponsor

Dan Bing

Who can join

Adults 4 to 65, any sex, with Sudden Sensorineural Hearing Loss or Hearing Loss, Sensorineural. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to describe the multi-omics characteristics and to learn about the prognostic factors in patients with idiopathic sudden sensorineural hearing loss (SSNHL). The main problems it aims to deal with are: * if there is a difference in data of exome and targeted sequencing among patients with SSNHL affecting bilateral and unilateral sides, and healthy controls * if there is a difference in the parameter of MRI among patients with SSNHL affecting bilateral and unilateral sides, and healthy controls * to find out which factor from multi-omics data relates to outcomes of SSNHL * to develop the best prognostics model based on the multi-omics data. Participants will be received audiological tests, blood specimen collection and radiological examination. Researchers will explore the relationship between the multi-omics data and the prognosis and develop the predictive model.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sudden Sensorineural Hearing Loss

Currently open trials in the same condition.

Other Dan Bing trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06365775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing